For Bayview Psychiatry Researchers - Data Core
Clinical Addiction Research Programs
- Addiction Treatment Services (ATS)
- Behavioral Biology Division
- Behavioral Pharmacology Research Unit (BPRU)
- Center for Addiction and Pregnancy (CAP)
- Center for Learning and Health(CLH)
- National Drug Abuse Treatment (NDAT) Clinical Trials Network: Mid-Atlantic Node
- Delirium Research
- Memory and Alzheimer's Treatment Center Research
- Late Life Mood Disorders Research
- Services Research
Behavioral Medicine Research
- Center for Behavior and Health
- Chronic Pain Research
- Sleep Medicine Research
The Division of Behavioral Biology at the Johns Hopkins Bayview Medical Center is characterized by a joining together of scientific interests, methods, and data with a common goal of an integrated understanding of behavior. A particular strength of the Division is development and use of methods for preclinical studies of operant behavior, including that representing cognitive function. Our current work encompasses studying the effects of centrally acting drugs and of radiation on behavior as well as studying pharmacological variables that determine or have the potential to treat drug misuse and dependence. We also conduct preclinical assessments of the abuse liability and dependence potential of drugs in development for clinical use.
Director: Denis Antoine, M.D.
Administrative Director: Dana Madden, LCPC
The Center for Addiction and Pregnancy (CAP) at the Johns Hopkins Bayview Medical Centeris a community-based treatment center located on the campus of The Johns Hopkins Bayview Medical Center. Since its inception in 1991, CAP has been committed to generating evidence-based research and applying these findings to improve the treatment provided. Given the various disciplines involved in the program (obstetrics, pediatrics and psychiatry), this is an ideal setting for patients to receive comprehensive care. Research projects conducted at CAP have examined a wide variety of questions including optimal medication and counseling services for pregnant women with substance use disorders, the role of partners in the treatment process for women at the program, the cost and benefit of the services provided, and novel behavioral treatments for pregnant women with active substance use disorders.
The National Drug Abuse Treatment Clinical Trials Network (CTN) was established by the National Institute on Drug Abuse (NIDA) in 1999 to improve substance abuse treatment nationwide. This is accomplished by conducting effectiveness research in community-based clinics and fostering adoption of evidence-based interventions and practices.
The Mid-Atlantic Node of the CTN is based in the Johns Hopkins Department of Psychiatry and Behavioral Sciences on the Bayview Campus and has collaborative affiliations with Virginia Commonwealth University (VCU), Friends Research Institute (FRI), and several local drug abuse treatment providers. Participating JHU faculty include Dr. Maxine Stitzer, Node Principal Investigator, and Dr. George Bigelow. Other affiliated faculty include Drs. Dace Svikis (VCU), Ellinore McCance-Katz (VCU) and Robert Schwartz (FRI).
The Mid-Atlantic Node has been actively involved in several national research studies and served as lead on a large multi-site trial that demonstrated effectiveness of prize-based incentives for improving treatment outcome in both methadone maintenance and psychosocial counseling treatment programs. Primary study results can be found in the Archives of General Psychiatry (Petry et al., 2005; Peirce et al., 2006).
For more information about the National Drug Abuse Treatment Clinical Trials Network go to www.nida.nih.gov/CTN/Research.html.